biosimilars Christopher Ko was appointed as the Chief Executive Officer of Samsung Bioepis in 2012, then newly founded Korean pharmaceutical company with expertise in biosimilars. In this interview, he discusses the opportunities in Biosimilar markets as well as the potential impact the Samsung brand will bring to the pharmaceutical industry. As…
biosimilars Brothers Juan José and Andrés Aguirre Salazar of Grupo Bruluart talk about the company’s most important milestones and how they are institutionalizing the family business to prepare the firm for new market opportunities. Could you walk us through the most important milestones of the company and provide our readers with…
investemnt The stability of Peru’s economy in recent years has provided amply opportunity for multinational pharmaceutical companies to invest in the country. Augusto Rey de la Cuba, executive director of ALAFARPE (Asociación Nacional de Laboratorios Faramcéuticos de Perú), discusses intellectual property issues and investing in research in the country. Can you…
biosimilar Laboratorios Elea’s General Manager tells the story of the laboratories outstanding growth over the previous five years, the his firms upcoming launch of the first Argentinian developed biosimilar product. To begin, would you please introduce yourself and Elea to our readers? I joined Elea four years ago as general manager,…
Biosimilars Dr. Liu, President and CEO of EirGenix, talks about why he sees Taiwan as the ideal market for a CDMO like Eirgenix, why he believes that despite the skepticism, biosimilars will be able to overcome the initial barriers, and where he sees EiGenix in the next several years. What has…
Biosimilars Audrey Tseng, Deputy Chairman of PwC Taiwan with PwC Partners Lily Wong and Andy Chang, delve into factors behind the booming pharma and biotech industry in Taiwan, how to prevent a bubble burst, and the crucial next steps in maintaining the momentum to continue growth within the industry. Please start…
Biosimilars Jaw-Jou Kang, former Director General of Taiwan Food & Drug Administration (TFDA) discusses the key successes the company has had since 2010, where it is looking to in the future and how a relationship with China would be mutually beneficial for both countries. Since Taiwan Food & Drug Administration’s founding…
Biosimilars Jim Keon, Preisdent of CGPA, discusses the cost-saving benefits that generic drugs have offered Canada, and offers his insights into Canada’s intellectual property regime and the challenges of pricing in Canada. As a privileged witness to the evolution of the Canadian generic industry, what have been some of the defining…
See our Cookie Privacy Policy Here
